Clinical Next Generation Sequencing Of Tumors: Potential, Advantages And Future Prospects | 16413
Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Next Generation Sequencing (NGS) represents a revolutionary high throughput sequencing technology, which enables
massive parallel sequencing of tens and hundreds of genes utilizing a single investment of low quantity of DNA. This
technology represents a major advantage over the single gene and low throughput sequencing platforms, which when needed
to screen for multiple markers are labor intensive, have high DNA requirements and expensive. As the number of markers to be
routinely screened in cancer diagnostics is increasing, NGS is being rapidly adapted for routine mutational screening of both
solid tumors and hematological malignancies in diagnostic labs. However, application of these technologies in diagnostic arena
also presents several challenges, which includes rigorous validation of these relatively new technologies to assess their suitability
for routine diagnostics, evolving guidelines for validation and application and need for special bioinformatics and clinical
reporting infrastructure. Rapid changes and improvements of the wet bench and analytical technology also warrant frequent
revalidations before induction for clinical use. The need for changes in billing and reimbursement format to accommodate NGS
into the model of single-gene tests and reporting of incidental findings also raise financial and ethical challenges, respectively.
Rajesh Singh has a Ph.D. in Biochemistry from The University of Mysore, India and Postdoctoral research experience from University of Texas, MD Anderson Cancer
Center. He has extensive experience in cancer biology focusing on the deregulated oncogenic and tumor suppressor pathways in the origin and maintenance
of solid tumors and hematological malignancies. He is an Assistant Professor in the molecular diagnostics laboratory at MD Anderson, where he supervises the
development team involved in design and validation of the NGS assays for routine mutational screening of tumors. He has published more than 36 papers and 3
review articles in reputed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals